Published on December 20, 2018
Is it safe for minimal residual disease (MRD)-negative patients stop treatment? At the 2018 American Society of Hematology (ASH) annual meeting in San Diego, noted myeloma expert Dr. Gareth Morgan, from The UAMS Myeloma Institute, joins Patient Power to share data-based recommendations on the use of maintenance therapy for MRD-negative status multiple myeloma patients. Watch now to find out more.
Transcript | Should MRD-Negative Patients Stay on Maintenance Therapy?
Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.
So, MRD negativity. So, you can’t—you look for the cancer cell. And even with some tests now, one in a million right?
One in a million cells. So, that’s what we’re trying to get to. Have treatments that are successful. Do a test. And then say to the patient, “We’ve knocked this back. We don’t know if you’re cured. But we’ve knocked it back to completely undetectable levels with our most sensitive testing.”
So, it’s a very good end point. It tells you people are going to do well. But it’s not an end point that says, “Stop treatment.” Because a couple of abstracts here. Certainly, the ixazomib (Ninlaro) maintenance data shows that even if you’re in MRD-negative state, having the maintenance improves your outcome even further. And so…
…just extends it. Yeah.
Yeah, absolutely. And so, we have to be thinking about patients’ quality of life, durability of ongoing therapy, total cost. But actually, I think within the cost envelope we have now, I think there’s a lot of room for maneuver that really is going to see patients having their progression-free and overall survival pushed out. So, very good numbers.